Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus late pharmacologic thromboprophylaxis after traumatic brain injury
ISRCTN64696029Phase 4Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium, heparin and fondaparinux in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Symptomatic deep vein thrombosis or pulmonary embolism within 30 days. Started Jun 2025; status: recruiting.
02
Drugs
low molecular weight heparin calciumheparinfondaparinux
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ISRCTN64696029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64696029.